SAT-541 Empagliflozin Induced Acute Pancreatitis
Abstract
Abstract Disclosure: H. Marasandra Ramesh: None. T. Hammad: None. S. Zahra: None. J. Ma: None. V. Zeykan: None. Introduction: Empagliflozin is a sodium-glucose co-transporter inhibitor used in the treatment of type 2 diabetes mellitus. They effectively decrease blood glucose levels by reducing renal reabsorption of glucose. Common adverse effects associated with it are urinary tract infections, and genitourinary fungal infections. Here, we report a case of empagliflozin- induced pancreatitis as a rare side effect. Case presentation: A 65-year-old male with a past medical history of type 2 diabetes mellitus on metformin, insulin lispro and glargine, empagliflozin, gastroesophageal reflux, hypertension, presented to the hospital with chief complaints of epigastric pain for 2 weeks associated with diarrhea. Detailed medication reconciliation history was relevant for initiation of empagliflozin 3 months prior to the presentation. The epigastric pain was 8/10 in intensity at times, radiating to the back and occasionally waking him up from sleep. He also had a couple of episodes of diarrhea in 1 week. He endorsed having decreased appetite and had lost about 40 lbs in the last 4 months. He had chronic symptoms of reflux which worsened in the last one week. Social history negative for smoking and alcohol intake. Physical examination pertinent for epigastric tenderness and groin fungal infection. Labs revealed mildly elevated lipase levels of 84 U/L, normal liver function tests,…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.